CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect.

Liu, Mingyue; Wang, Xu; Du, Xuexiang; Zhang, Yan; Ai, Chunxia; Hu-Lieskovan, Siwen; Li, Tianhong; Devenport, Martin; Liu, Yang; Zheng, Pan

Liu, Mingyue; Wang, Xu; Du, Xuexiang; Zhang, Yan; Ai, Chunxia; Hu-Lieskovan, Siwen; Li, Tianhong; Devenport, Martin; Liu, Yang; Zheng, Pan.

Liu M; Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
Wang X; Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
Du X; Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
Zhang Y; Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, China.
Ai C; Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
Hu-Lieskovan S; Shanghai Institute of Immunology, Department of Immunology and Microbiology, State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Li T; Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, 21202, USA.
Devenport M; Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, China.
Liu Y; Division of Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Zheng P; Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA.

Signal Transduct Target Ther ; 7(1): 224, 2022 07 15.

Artigo em Inglês | MEDLINE | ID: covidwho-2008258

Assuntos

Doenças do Sistema Imunitário; Neoplasias; Humanos; Fatores Imunológicos; Neoplasias/tratamento farmacológico; Neoplasias/genética; Neoplasias/patologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Doenças do Sistema Imunitário / Neoplasias Tipo de estudo: Estudo experimental Limite: Humanos Idioma: Inglês Revista: Signal Transduct Target Ther Ano de publicação: 2022 Tipo de documento: Artigo País de afiliação: S41392-022-01030-x

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google